Literature DB >> 2871880

The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat.

T Abrahamsson.   

Abstract

The rat isolated right atrium (frequency response) and progesterone-treated rat uterus (relaxation) were used to examine the beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol. In addition, the beta 1-adrenoceptor stimulatory effect of practolol was studied in the right atrium. All the compounds studied caused a concentration-dependent increase in atrial frequency and relaxation of the uterus. The atrial response to pindolol was competitively inhibited by the beta 1-selective blocker pafenolol (10(-7) M), while the beta 2-selective blocker ICI 118551 (10(-8) M) was without effect. Pafenolol (10(-7) M) was also shown to inhibit the atrial frequency effect of alprenolol and oxprenolol. In the uterus, ICI 118551 (3 X 10(-9) M, 3 X 10(-8) M, 3 X 10(-7) M) blocked the pindolol effect with a pKB of 9.28. In addition, ICI 118551 (10(-8) M) competitively inhibited the relaxation of the uterus induced by alprenolol and oxprenolol. For alprenolol (right atrium and uterus), oxprenolol (right atrium), and pindolol (right atrium), the concentrations needed for half-maximal response were significantly greater than those required for occupation of half the receptors. This dissociation was most pronounced for pindolol in the right atrium. In this tissue, 80-85% of the beta 1-adrenoceptors had to be occupied by pindolol to initiate a tissue response corresponding to 50% of the maximal effect generated by the compound. The intrinsic activities of alprenolol, oxprenolol and pindolol (expressed as % of the maximal tissue response to isoprenaline) were significantly higher in the uterus than in the right atrium. The intrinsic activity of the compounds varied between individual preparations and, particularly in the uterus, correlated with the sensitivity of the tissue to beta-adrenoceptor stimulation by isoprenaline. 5 Calculation ofefficacy, relative to isoprenaline, of the partial beta-agonists revealed a beta 2-adrenoceptor selectivity for alprenolol (2.0), oxprenolol (1.4) and pindolol (3.0). 6 It is concluded that weak partial agonists such as alprenolol, oxprenolol and pindolol possess complex beta 1- and beta 2-adrenoceptor stimulatory properties in relation to beta-adrenoceptor occupancy and tissue sensitivity to beta-adrenoceptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871880      PMCID: PMC1916803          DOI: 10.1111/j.1476-5381.1986.tb14582.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  On spare beta-adrenoceptors of inotropic effect of catecholamines in kitten ventricle.

Authors:  A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-11       Impact factor: 3.000

2.  Intrinsic sympathomimetic activity of the partial agonist prenalterol in relation to beta adrenoceptor interaction in various tissues, in vitro.

Authors:  H Mattsson; A Hedberg; E Carlsson
Journal:  J Pharmacol Exp Ther       Date:  1983-03       Impact factor: 4.030

3.  Theoretical and practical problems with the assessment of intrinsic efficacy of agonists: efficacy of reputed beta-1 selective adrenoceptor agonists for beta-2 adrenoceptors.

Authors:  T P Kenakin
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

4.  Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships.

Authors:  T P Kenakin; D Beek
Journal:  J Pharmacol Exp Ther       Date:  1980-05       Impact factor: 4.030

5.  beta-Adrenoceptor blocking agents as partial agonists in isolated heart muscle: dissociation of stimulation and blockade.

Authors:  A J Kaumann; J R Blinks
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-04       Impact factor: 3.000

6.  Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists.

Authors:  R B Parker; D R Waud
Journal:  J Pharmacol Exp Ther       Date:  1971-04       Impact factor: 4.030

7.  The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551).

Authors:  A J Bilski; S E Halliday; J D Fitzgerald; J L Wale
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

8.  Beta adrenoceptor interaction of full and partial agonists in the cat heart and soleus muscle.

Authors:  A Hedberg; H Mattsson
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

9.  Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding.

Authors:  O E Brodde; K Karad; H R Zerkowski; N Rohm; J C Reidemeister
Journal:  Circ Res       Date:  1983-12       Impact factor: 17.367

10.  beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol.

Authors:  H Mattsson; T Andersson; E Carlsson; A Hedberg; B Lundgren; T Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

View more
  4 in total

1.  Effects of chronic pindolol treatment on human myocardial beta 1- and beta 2-adrenoceptor function.

Authors:  R Bjørnerheim; S Golf; V Hansson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

2.  The role of endogenous noradrenaline in the beta-blocker withdrawal phenomenon--studies with cultured heart cells.

Authors:  C Reithmann; A Thomschke; K Werdan
Journal:  Klin Wochenschr       Date:  1987-04-01

3.  Desensitization pattern of cardiac beta-adrenoceptor subtypes by prolonged in vivo infusion of pindolol and celiprolol in rats.

Authors:  C Nanoff; M Ströher; H Haschkowitz; W Schütz; H Pittner
Journal:  Basic Res Cardiol       Date:  1990 Jan-Feb       Impact factor: 17.165

4.  The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study.

Authors:  Johannes T H Nielen; Frank de Vries; Jeroen H P M van der Velde; Hans H C M Savelberg; Nicolaas C Schaper; Pieter C Dagnelie; Ronald M A Henry; Miranda Schram; Coen D A Stehouwer; Annelies Boonen; Annemarie Koster; Bart J F van den Bemt
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-05-24       Impact factor: 2.457

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.